Cargando…
Potential Excess Mortality in BRCA1/2 Mutation Carriers beyond Breast, Ovarian, Prostate, and Pancreatic Cancers, and Melanoma
BACKGROUND: Although the increase in risk of developing breast, ovarian, and prostate cancer in BRCA1 and BRCA2 mutation carriers has been studied extensively, its impact on mortality is not well quantified. Further, possible effect of BRCA mutations on non-cancer mortality risk has not been examine...
Autores principales: | Mai, Phuong L., Chatterjee, Nilanjan, Hartge, Patricia, Tucker, Margaret, Brody, Lawrence, Struewing, Jeffery P., Wacholder, Sholom |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2652075/ https://www.ncbi.nlm.nih.gov/pubmed/19277124 http://dx.doi.org/10.1371/journal.pone.0004812 |
Ejemplares similares
-
Kin-cohort estimates for familial breast cancer risk in relation to variants in DNA base excision repair, BRCA1 interacting and growth factor genes
por: Sigurdson, Alice J, et al.
Publicado: (2004) -
A new statistic and its power to infer membership and phenotype in a genome-wide association study using genotype frequencies
por: Jacobs, Kevin B., et al.
Publicado: (2009) -
PARP inhibitors in BRCA1/BRCA2 germline mutation carriers with ovarian and breast cancer
por: Annunziata, Christina M, et al.
Publicado: (2010) -
Outcome of ovarian cancer after breast cancer in BRCA1 and BRCA2 mutation carriers
por: Zaaijer, Leendert H, et al.
Publicado: (2016) -
Hereditary Ovarian Carcinoma: Cancer Pathogenesis Looking beyond BRCA1 and BRCA2
por: Samuel, David, et al.
Publicado: (2022)